Kazuo Fujihara Selected Research

Aquaporin 4

1/2021	Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
3/2020	Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD).
1/2020	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide.
1/2020	Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes.
1/2020	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD.
10/2016	Different etiologies and prognoses of optic neuritis in demyelinating diseases.
12/2015	Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS.
3/2015	The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model.
9/2014	A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion.
1/2014	[A case of myelitis with anti-aquaporin 4 antibody concomitant with immune thrombocytopenic purpura].

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazuo Fujihara Research Topics

Disease

87	Neuromyelitis Optica (Devic's Disease) 05/2022 - 04/2004
39	Multiple Sclerosis 01/2022 - 11/2002
23	Optic Neuritis (Retrobulbar Neuritis) 01/2022 - 01/2011
20	Demyelinating Diseases (Demyelinating Disease) 01/2021 - 08/2007
9	Myelitis 01/2020 - 11/2006
8	Encephalitis (Encephalitis, Rasmussen) 01/2020 - 11/2009
7	Infections 05/2022 - 01/2012
5	Leukocytosis (Pleocytosis) 01/2019 - 11/2007
5	Necrosis 06/2013 - 10/2004
4	Pain (Aches) 01/2021 - 01/2012
4	Autoimmune Diseases (Autoimmune Disease) 11/2019 - 05/2003
4	Transverse Myelitis (Necrotizing Myelitis) 01/2016 - 01/2012
4	Inflammation (Inflammations) 09/2015 - 03/2011
3	Fatigue 01/2021 - 06/2015
3	Encephalomyelitis (Myeloencephalitis) 01/2020 - 12/2015
3	Blindness (Hysterical Blindness) 10/2019 - 11/2006
3	Disease Progression 01/2018 - 10/2015
3	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 12/2015 - 10/2004
3	Tropical Spastic Paraparesis (Tropical Spastic Paraplegia) 02/2005 - 08/2003
2	Human Influenza (Influenza) 05/2022 - 11/2014
2	Respiratory Tract Infections (Respiratory Tract Infection) 05/2021 - 01/2019
2	Headache (Headaches) 05/2021 - 01/2019
2	Aphasia (Dysphasia) 01/2018 - 09/2014
2	Poisoning 01/2016 - 05/2015
2	Acute Disseminated Encephalomyelitis (Postinfectious Encephalomyelitis) 01/2016 - 10/2015
2	Central Nervous System Diseases (CNS Diseases) 12/2015 - 10/2015
2	Spinal Cord Diseases 03/2015 - 08/2003
2	Granuloma 03/2011 - 02/2002
2	Opticospinal Multiple Sclerosis 01/2011 - 11/2007
2	Polymyositis 11/2006 - 02/2002
2	Myositis (Idiopathic Inflammatory Myopathies) 12/2005 - 02/2002
1	Hepatitis E 05/2022
1	Atrophy 01/2022
1	Vision Disorders (Hemeralopia) 01/2022
1	Ganglion Cysts (Ganglion) 01/2022
1	Nasopharyngitis 05/2021
1	Microscopic Polyangiitis 04/2021
1	Wounds and Injuries (Trauma) 01/2021
1	Gliosis 01/2021
1	Chronic Disease (Chronic Diseases) 11/2019
1	Paralysis (Palsy) 10/2019
1	Empyema 01/2019
1	Immune Reconstitution Inflammatory Syndrome 01/2018
1	Herpes Zoster 01/2018
1	Progressive Multifocal Leukoencephalopathy 01/2018
1	Paresis (Hemiparesis) 01/2018
1	Paraparesis 01/2017

Drug/Important Bio-Agent (IBA)

33	Immunoglobulin G (IgG)IBA 03/2022 - 12/2004
31	AntibodiesIBA 01/2021 - 11/2009
28	AutoantibodiesIBA 05/2021 - 12/2004
22	Myelin-Oligodendrocyte GlycoproteinIBA 01/2022 - 02/2014
19	Aquaporin 4IBA 01/2021 - 11/2010
12	Complement System Proteins (Complement)IBA 01/2021 - 06/2008
10	Aquaporins (Water Channels)IBA 05/2021 - 05/2007
8	ChemokinesIBA 11/2016 - 08/2003
7	eculizumab FDA Link 01/2022 - 01/2019
7	Biomarkers (Surrogate Marker)IBA 01/2021 - 09/2010
7	Oligoclonal BandsIBA 01/2018 - 06/2004
6	anti-aquaporin 4 autoantibodyIBA 01/2016 - 05/2008
5	SteroidsIBA 05/2022 - 12/2014
5	Proteins (Proteins, Gene)FDA Link 03/2017 - 01/2005
5	InterferonsIBA 06/2015 - 10/2004
5	AntigensIBA 09/2011 - 05/2007
4	inebilizumabIBA 01/2022 - 10/2019
4	Retinaldehyde (Retinal)IBA 01/2022 - 12/2010
4	Glial Fibrillary Acidic ProteinIBA 01/2020 - 05/2008
4	Methylprednisolone FDA LinkGeneric 01/2020 - 05/2008
4	CytokinesIBA 11/2016 - 10/2004
3	satralizumabIBA 05/2022 - 11/2019
3	Prednisolone (Predate)FDA LinkGeneric 04/2021 - 05/2015
3	Interleukin-6 (Interleukin 6)IBA 01/2020 - 08/2014
3	Immunosuppressive Agents (Immunosuppressants)IBA 11/2019 - 11/2007
3	Protons (Proton)IBA 01/2016 - 04/2003
3	Monoclonal AntibodiesIBA 01/2016 - 06/2008
3	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2015 - 10/2003
3	Therapeutic UsesIBA 12/2014 - 02/2005
3	Immunoglobulins (Immunoglobulin)IBA 11/2009 - 11/2006
3	Interferon-alpha (Interferon Alfa)IBA 02/2005 - 08/2003
2	Rituximab (Mabthera)FDA Link 01/2021 - 07/2011
2	EnzymesIBA 01/2020 - 08/2007
2	Fingolimod Hydrochloride (FTY720)FDA Link 01/2018 - 03/2014
2	Myelin Basic ProteinIBA 03/2017 - 05/2012
2	EpitopesIBA 10/2016 - 01/2011
2	Carbon MonoxideIBA 01/2016 - 05/2015
2	Interferon-betaIBA 02/2008 - 11/2007
1	Endoplasmic Reticulum Chaperone BiPIBA 01/2022
1	Complement Inactivating AgentsIBA 05/2021
1	Biological ProductsIBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2021
1	Myelin-Associated GlycoproteinIBA 01/2021
1	Glutamate-Ammonia Ligase (Glutamine Synthetase)IBA 01/2020
1	HLA-B51 AntigenIBA 01/2019
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2018
1	GadoliniumIBA 07/2017
1	Glutamate Receptors (Glutamate Receptor)IBA 03/2017
1	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 03/2017

Therapy/Procedure

23	Therapeutics 04/2021 - 10/2003
2	Immunotherapy 01/2012 - 02/2002
1	Secondary Prevention 01/2021